Abcam, ab226836, Anti-IRF7 antibody

Size: 100µL
Rabbit Polyclonal IRF7 antibody. Suitable for WB and reacts with Human samples. Cited in 2 publications. Immunogen corresponding to Recombinant Fragment Protein within Human IRF7.
Key facts
Host species:Rabbit,
Clonality:Polyclonal,
Isotype:IgG,
Carrier free:No,
Reacts with:Human,
Applications:WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:Recombinant Fragment Protein within Human IRF7. The exact immunogen used to generate this antibody is proprietary information.Q92985

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Immunogen, Storage buffer-pH: 7Preservative: 0.025% Proclin 300Constituents: PBS, 20% Glycerol (glycerin, glycerine), Shipped at conditions-Blue Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions--20°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The transcription factor IRF7 also known as Interferon Regulatory Factor 7 plays a significant role in the regulation of type I interferon genes. This protein acts as an important modulator of the immune response specifically during viral infections. The molecular weight of IRF7 is approximately 54 kDa. It is predominantly expressed in lymphoid tissues such as the spleen and thymus and is also found in other immune cells like B cells and dendritic cells. The expression of IRF7 is induced by pathogen-associated molecular patterns which stimulate the activation of immune signaling pathways.
Biological function summary
IRF7 activates and modulates the expression of type I interferons and other cytokines important for antiviral defense. This protein can form part of a larger complex with other IRF family members to enhance its effect on gene transcription. IRF7 operates through its interaction with transcriptional coactivators allowing it to execute its function as a transcriptional activator reinforcing the immune system's response to infectious agents.
Pathways
IRF7 plays a critical role in the Toll-like receptor (TLR) signaling pathway and retinoic acid-inducible gene I (RIG-I) pathway. It directly interacts with MyD88 and IRAK1 proteins linking it to signal transduction pathways that lead to interferon-beta production. The activation of IRF7 in these pathways also strengthens the body's defense mechanism by enhancing the transcription of antiviral genes forming a robust antibacterial and antiviral environment within the host.
IRF7's function is implicated in autoimmune diseases and specific cancers. For autoimmune conditions like systemic lupus erythematosus (SLE) dysregulated IRF7 activity is observed leading to an aberrant interferon response. It connects with proteins such as IRF5 which has its expressions elevated in affected patients. In relation to cancer IRF7 can impact tumor progression particularly in breast cancer through modulation of immune surveillance functions. Its interaction with interferon pathways becomes a double-edged sword affecting tumor immunity and progression.